Publications

               

[*Correspondence]

University of Tennessee (2018 – Present)

  • Li L, Yasmen N, Hou R, Yang S, Lee SY, Hao J, Yu Y, and Jiang J* (2022) Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke. Neurotherapeutics (Accepted)
  • Fu H, Wang J, Wang J, Liu L, Jiang J, and Hao J (2022) 4R-cembranoid protects neuronal cells against oxygen-glucose deprivation by modulating microglial cell activation. Brain Research Bulletin 179:74-82.
  • Sluter MN, Hou R, Li L, Yasmen N, Yu Y, Liu J, and Jiang J* (2021) EP2 Antagonists (2011-2021): A Decade’s Journey from Discovery to Therapeutics. Journal of Medicinal Chemistry 64:11816-11836.
  • Xu X, Du L, Jiang J, Yang M, Wang Z, Wang Y, Tang T, Fu X, and Hao J (2021). Microglial TREM2 Mitigates Inflammatory Responses and Neuronal Apoptosis in Angiotensin II-Induced Hypertension in Middle-Aged Mice. Frontiers in Aging Neuroscience 13:716917.
  • Xu X, Zhang C, Jiang J, Xin M, and Hao J (2021) The TDP43 CFTS Affect Brain Endothelial Cell Functions by Regulating YAP and Tight Junction Proteins in Cerebral Ischemic Injury. Research Square:rs-762288/v1.
  • Jiang J* and Yu Y (2021) Small molecules targeting cyclooxygenase/prostanoid cascade in experimental brain ischemia: Do they translate? Medicinal Research Reviews 41:828-857.
  • Hou R*, Yu Y, and Jiang J* (2021) PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency. Biochemical Pharmacology 184:114363.
  • Li L, Sluter MN, Yu Y, and Jiang J* (2021) Prostaglandin E receptors as targets for ischemic stroke: Novel evidence and molecular mechanisms of efficacy. Pharmacological Research 163:105238.
  • Yu Y and Jiang J* (2020) COX-2/PGE2 axis regulates hippocampal BDNF/TrkB signaling via EP2 receptor after prolonged seizures. Epilepsia Open 5:418-431. (2021 Epilepsia Open Prize for Basic Science)
  • Li L, Yu Y, Hou R, Hao J, and Jiang J* (2020) Inhibiting the PGE2 Receptor EP2 Mitigates Excitotoxicity and Ischemic Injury. ACS Pharmacology & Translational Science 3:635-643.
  • Hou R, Yu Y, Nguyen DT, Sluter MN, Li L, Yang J, and Jiang J* (2020) Prostaglandin receptor EP2 is a novel molecular target for high-risk neuroblastoma. bioRxiv:2020.2002.2024.963108. (Preprint)
  • Yu Y, Li L, Nguyen DT, Mustafa SM, Moore BM, and Jiang J* (2020) Inverse agonism of cannabinoid receptor type 2 confers anti-inflammatory and neuroprotective effects following status epilepticus. Molecular Neurobiology 57:2830-2845.
  • Nagib MM, Yu Y, and Jiang J* (2020) Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus. Pharmacology & Therapeutics 209:107504.
  • Yu Y, Nguyen DT, and Jiang J* (2019) G protein-coupled receptors in acquired epilepsy: Druggability and translatability. Progress in Neurobiology 183:101682.
  • Dawn A, Yao X, Yu Y, Jiang J*, and Kumari H* (2019) Assessment of the in vitro toxicity of calixarenes and a metal-seamed calixarene: a chemical pathway for clinical application. Supramolecular Chemistry 31:425-431.
  • Qiu J, Li Q, Bell KA, Yao X, Du Y, Zhang E, Yu JJ, Yu Y, Shi Z*, and Jiang J* (2019) Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth. British Journal of Pharmacology 176:1680-1699.
  • Jiang J*, Yu Y, Kinjo E, Du Y, Nguyen H, and Dingledine R (2019) Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology 149:149-160.

University of Cincinnati (2015 – 2018)

  • Jiang J*, Van TM, Ganesh T, and Dingledine R (2018) Discovery of 2-piperidinyl phenyl benzamides and trisubstituted pyrimidines as positive allosteric modulators of the prostaglandin receptor EP2. ACS Chemical Neuroscience 9:699-707.
  • Hartings JA, York J, Carroll CP, Hinzman JM, Mahoney E, Krueger B, Winkler MKL, Major S, Horst V, Jahnke P, Woitzik J, Kola V, Du Y, Hagen M, Jiang J, and Dreier JP (2017) Subarachnoid blood acutely induces spreading depolarizations and early cortical infarction. Brain 140:2673-2690.
  • Kang X, Qiu J, Li Q, Bell KA, Du Y, Jung DW, Lee JY, Hao J, and Jiang J* (2017) Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Scientific Reports 7:9459.
  • Jiang J*, Qiu J, Li Q, and Shi Z* (2017) Prostaglandin E2 signaling: alternative target for glioblastoma? Trends in Cancer 3:75-78.
  • Qiu J, Shi Z*, and Jiang J* (2017) Cyclooxygenase-2 in glioblastoma multiforme. Drug Discovery Today 22:148-156.
  • Dey A, Kang X, Qiu J, Du Y, and Jiang J* (2016) Anti-inflammatory small molecules to treat seizures and epilepsy: from bench to bedside. Trends in Pharmacological Sciences 34:413-423.
  • Du Y, Kemper T, Qiu J, and Jiang J* (2016) Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus. Expert Review of Neurotherapeutics 16:123-130.
  • Du Y, Seibenhener ML, Yan J, Jiang J, and Wooten MC (2015) aPKC phosphorylation of HDAC6 results in increased deacetylation activity. PLOS ONE 10:e0123191.
  • Fu Y, Yang M-S, Jiang J, Ganesh T, Joe E, and Dingledine R (2015) EP2 receptor signaling regulates microglia death. Molecular Pharmacology 88:161-170.
  • Jiang J*, Yang M-S, Quan Y, Gueorguieva P, Ganesh T, and Dingledine R (2015) Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiology of Disease 76:126-135.
  • Varvel NH*, Jiang J*, and Dingledine R* (2015) Candidate drug targets for prevention or modification of epilepsy. Annual Review of Pharmacology and Toxicology 55:229-247.

Prior to 2015